Pharma Reviews: We expect big numbers to kick in from FY20-FY21: Kiran Mazumdar Shaw, Biocon

The signalling should be that Biocon has complied with all USFDA problems and unlike other Indian pharma companies, decks are cleared for Biocon ...
Read more: We expect big numbers to kick in from FY20-FY21: Kiran Mazumdar Shaw, Biocon